MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
07 März 2024 - 1:30PM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant
natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases, today announced that the Company will
release its fourth quarter and year-end 2023 financial results
before the market opens on Thursday, March 21, 2024. MiNK
executives will host a conference call and webcast at 8:30 a.m. ET
that morning to discuss the results and to provide a corporate
update.
Conference Call
Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S.
& Canada)
Conference ID: 1391457
Webcast
A live webcast and replay of the conference call will be
accessible from the Events & Presentations page of the
Company’s website at
https://investor.minktherapeutics.com/events-and-presentations and
via https://edge.media-server.com/mmc/p/xa2m5uy7.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery, development, and commercialization of
allogeneic invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases. MiNK is advancing
a pipeline of both native and next generation engineered iNKT
programs, with a platform designed to facilitate scalable and
reproducible manufacturing for off-the-shelf delivery. The company
is headquartered in New York, NY. For more information, visit
https://minktherapeutics.com/ or @MiNK_iNKT. Information that may
be important to investors will be routinely posted on our website
and social media channels.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Jan 2024 bis Jan 2025